179 related articles for article (PubMed ID: 20868368)
1. Transforming JAK1 mutations exhibit differential signalling, FERM domain requirements and growth responses to interferon-γ.
Gordon GM; Lambert QT; Daniel KG; Reuther GW
Biochem J; 2010 Dec; 432(2):255-65. PubMed ID: 20868368
[TBL] [Abstract][Full Text] [Related]
2. Dual role of the Jak1 FERM and kinase domains in cytokine receptor binding and in stimulation-dependent Jak activation.
Haan S; Margue C; Engrand A; Rolvering C; Schmitz-Van de Leur H; Heinrich PC; Behrmann I; Haan C
J Immunol; 2008 Jan; 180(2):998-1007. PubMed ID: 18178840
[TBL] [Abstract][Full Text] [Related]
3. Acute lymphoblastic leukemia-associated JAK1 mutants activate the Janus kinase/STAT pathway via interleukin-9 receptor alpha homodimers.
Hornakova T; Staerk J; Royer Y; Flex E; Tartaglia M; Constantinescu SN; Knoops L; Renauld JC
J Biol Chem; 2009 Mar; 284(11):6773-81. PubMed ID: 19139102
[TBL] [Abstract][Full Text] [Related]
4. Distinct Acute Lymphoblastic Leukemia (ALL)-associated Janus Kinase 3 (JAK3) Mutants Exhibit Different Cytokine-Receptor Requirements and JAK Inhibitor Specificities.
Losdyck E; Hornakova T; Springuel L; Degryse S; Gielen O; Cools J; Constantinescu SN; Flex E; Tartaglia M; Renauld JC; Knoops L
J Biol Chem; 2015 Nov; 290(48):29022-34. PubMed ID: 26446793
[TBL] [Abstract][Full Text] [Related]
5. ALL-associated JAK1 mutations confer hypersensitivity to the antiproliferative effect of type I interferon.
Hornakova T; Chiaretti S; Lemaire MM; Foà R; Ben Abdelali R; Asnafi V; Tartaglia M; Renauld JC; Knoops L
Blood; 2010 Apr; 115(16):3287-95. PubMed ID: 20167706
[TBL] [Abstract][Full Text] [Related]
6. A JAK1/JAK2 chimera can sustain alpha and gamma interferon responses.
Kohlhuber F; Rogers NC; Watling D; Feng J; Guschin D; Briscoe J; Witthuhn BA; Kotenko SV; Pestka S; Stark GR; Ihle JN; Kerr IM
Mol Cell Biol; 1997 Feb; 17(2):695-706. PubMed ID: 9001223
[TBL] [Abstract][Full Text] [Related]
7. The molecular regulation of Janus kinase (JAK) activation.
Babon JJ; Lucet IS; Murphy JM; Nicola NA; Varghese LN
Biochem J; 2014 Aug; 462(1):1-13. PubMed ID: 25057888
[TBL] [Abstract][Full Text] [Related]
8. Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors.
Hornakova T; Springuel L; Devreux J; Dusa A; Constantinescu SN; Knoops L; Renauld JC
Haematologica; 2011 Jun; 96(6):845-53. PubMed ID: 21393331
[TBL] [Abstract][Full Text] [Related]
9. Identification of a novel functional JAK1 S646P mutation in acute lymphoblastic leukemia.
Li Q; Li B; Hu L; Ning H; Jiang M; Wang D; Liu T; Zhang B; Chen H
Oncotarget; 2017 May; 8(21):34687-34697. PubMed ID: 28410228
[TBL] [Abstract][Full Text] [Related]
10. Mutations in the transmembrane and juxtamembrane domains enhance IL27R transforming activity.
Lambert QT; Pradhan A; Roll JD; Reuther GW
Biochem J; 2011 Aug; 438(1):155-64. PubMed ID: 21631431
[TBL] [Abstract][Full Text] [Related]
11. Differential role of Janus family kinases (JAKs) in interferon-gamma-induced lung epithelial ICAM-1 expression: involving protein interactions between JAKs, phospholipase Cgamma, c-Src, and STAT1.
Chang YJ; Holtzman MJ; Chen CC
Mol Pharmacol; 2004 Mar; 65(3):589-98. PubMed ID: 14978237
[TBL] [Abstract][Full Text] [Related]
12. JAK1 Pseudokinase V666G Mutant Dominantly Impairs JAK3 Phosphorylation and IL-2 Signaling.
Grant AH; Rodriguez AC; Rodriguez Moncivais OJ; Sun S; Li L; Mohl JE; Leung MY; Kirken RA; Rodriguez G
Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047778
[TBL] [Abstract][Full Text] [Related]
13. JAK mutations in high-risk childhood acute lymphoblastic leukemia.
Mullighan CG; Zhang J; Harvey RC; Collins-Underwood JR; Schulman BA; Phillips LA; Tasian SK; Loh ML; Su X; Liu W; Devidas M; Atlas SR; Chen IM; Clifford RJ; Gerhard DS; Carroll WL; Reaman GH; Smith M; Downing JR; Hunger SP; Willman CL
Proc Natl Acad Sci U S A; 2009 Jun; 106(23):9414-8. PubMed ID: 19470474
[TBL] [Abstract][Full Text] [Related]
14. Attenuation of gamma interferon-induced tyrosine phosphorylation in mononuclear phagocytes infected with Leishmania donovani: selective inhibition of signaling through Janus kinases and Stat1.
Nandan D; Reiner NE
Infect Immun; 1995 Nov; 63(11):4495-500. PubMed ID: 7591091
[TBL] [Abstract][Full Text] [Related]
15. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model.
Degryse S; de Bock CE; Cox L; Demeyer S; Gielen O; Mentens N; Jacobs K; Geerdens E; Gianfelici V; Hulselmans G; Fiers M; Aerts S; Meijerink JP; Tousseyn T; Cools J
Blood; 2014 Nov; 124(20):3092-100. PubMed ID: 25193870
[TBL] [Abstract][Full Text] [Related]
16. Biallelic JAK1 mutations in immunodeficient patient with mycobacterial infection.
Eletto D; Burns SO; Angulo I; Plagnol V; Gilmour KC; Henriquez F; Curtis J; Gaspar M; Nowak K; Daza-Cajigal V; Kumararatne D; Doffinger R; Thrasher AJ; Nejentsev S
Nat Commun; 2016 Dec; 7():13992. PubMed ID: 28008925
[TBL] [Abstract][Full Text] [Related]
17. JAK1 truncating mutations in gynecologic cancer define new role of cancer-associated protein tyrosine kinase aberrations.
Ren Y; Zhang Y; Liu RZ; Fenstermacher DA; Wright KL; Teer JK; Wu J
Sci Rep; 2013 Oct; 3():3042. PubMed ID: 24154688
[TBL] [Abstract][Full Text] [Related]
18. Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia.
Flex E; Petrangeli V; Stella L; Chiaretti S; Hornakova T; Knoops L; Ariola C; Fodale V; Clappier E; Paoloni F; Martinelli S; Fragale A; Sanchez M; Tavolaro S; Messina M; Cazzaniga G; Camera A; Pizzolo G; Tornesello A; Vignetti M; Battistini A; Cavé H; Gelb BD; Renauld JC; Biondi A; Constantinescu SN; Foà R; Tartaglia M
J Exp Med; 2008 Apr; 205(4):751-8. PubMed ID: 18362173
[TBL] [Abstract][Full Text] [Related]
19. Kinase-negative mutants of JAK1 can sustain interferon-gamma-inducible gene expression but not an antiviral state.
Briscoe J; Rogers NC; Witthuhn BA; Watling D; Harpur AG; Wilks AF; Stark GR; Ihle JN; Kerr IM
EMBO J; 1996 Feb; 15(4):799-809. PubMed ID: 8631301
[TBL] [Abstract][Full Text] [Related]
20. A region encompassing the FERM domain of Jak1 is necessary for binding to the cytokine receptor gp130.
Hilkens CM; Is'harc H; Lillemeier BF; Strobl B; Bates PA; Behrmann I; Kerr IM
FEBS Lett; 2001 Sep; 505(1):87-91. PubMed ID: 11557047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
